ALNY Alnylam Pharmaceuticals Inc

NASDAQ
$237.10

Alnylam Pharmaceuticals Inc (ALNY) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Subdued Selling ran below ALNY's own trailing one-year pace, with 32% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 1 seller in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
7
125 transactions
Purchases
$0
0 shares
Sales
$12.5M
38,799 shares
Net activity
-$12.5M
purchases less sales

How much of that selling was preplanned? 32% planned / 68% discretionary

10b5-1 plan sales $4.0M 26 transactions · 12,605 shares
Discretionary sales $8.5M 99 transactions · 26,194 shares

Largest single sale: $545.4K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
PYOTT DAVID E I 5 fills Director Sell 10b5-1 3,830 $299.18 $1.1M 4,491 −46% of holding
McLaughlin Melissa 5 fills Chief Human Resources Officer Sell 10b5-1 2,286 $330.42 $755.3K 11,673 −16.4% of holding
McLaughlin Melissa 9 fills Chief Human Resources Officer Sell 1,624 $319.59 $519.0K 13,088 −11% of holding
Garg Pushkal 4 fills EVP Chief R&D Sell 10b5-1 2,404 $323.96 $778.8K 20,443 −10.5% of holding
Fitzgerald Kevin Joseph 4 fills CSO & EVP, Head of Research Sell 10b5-1 658 $323.98 $213.2K 21,103 −3% of holding
Greenstreet Yvonne 8 fills Chief Executive Officer Sell 2,933 $323.08 $947.6K 98,493 −2.9% of holding
Poulton Jeffrey V. 8 fills EVP, Chief Financial Officer Sell 2,468 $323.08 $797.4K 64,159 −3.7% of holding
Garg Pushkal 8 fills EVP Chief R&D Sell 2,309 $323.08 $746.0K 23,300 −9% of holding
Tanguler Tolga 8 fills EVP, Chief Commercial Officer Sell 2,309 $323.08 $746.0K 36,500 −5.9% of holding
Fitzgerald Kevin Joseph 8 fills CSO & EVP, Head of Research Sell 633 $323.08 $204.5K 21,831 −2.8% of holding
Garg Pushkal 4 fills EVP Chief R&D Sell 10b5-1 1,775 $319.74 $567.5K 24,826 −6.7% of holding
Fitzgerald Kevin Joseph 4 fills CSO & EVP, Head of Research Sell 10b5-1 1,652 $319.73 $528.2K 23,223 −6.6% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.